Alpa Laboratories Limited (ALPA) AI Stock Analysis

• Market Cap: ₹1.47B
• Dividend Yield: N/A
• Average Volume (3M): 2.75K
• Price to Earnings (P/E): 21.5
• Beta (1Y): 1.26
• Revenue Growth: 14.53%
• EPS Growth: -10.49%
• Country: IN
• Employees: 410
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.90
• Shares Outstanding: 21,040,600
• 10 Day Avg. Volume: 3,648
• 30 Day Avg. Volume: 2,746
• PEG Ratio: 0.73
• Price to Book (P/B): 1.31
• Price to Sales (P/S): 2.00
• P/FCF Ratio: -104.73
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 64 Neutral
• Price Target: ₹74.00 ▼(-2.12% Downside)
• Action: Reiterated Date: 04/08/26
• Date: Action: Reiterated 04/08/26

The score is primarily driven by strong growth and profitability plus an exceptionally low-leverage balance sheet, tempered by negative free cash flow and weak cash conversion. Technicals are mixed (short-term strength but longer-term downtrend and negative MACD), and valuation appears moderate with no dividend data to add support.

Positive Factors

Revenue Growth

Consistent ~17% revenue growth indicates durable demand for the company's pharmaceutical products and supports longer-term top-line expansion. Sustained revenue momentum provides capacity to invest in R&D, expand market reach, and amortize fixed costs, improving long-run profitability if trends persist.

Negative Factors

Weak Cash Conversion / Negative FCF

Negative free cash flow and a low operating-cash-to-net-income ratio indicate earnings are not being converted into cash efficiently. Over months this can constrain capital for capex, working capital, dividends, or M&A, forcing reliance on external funding or equity issuance and reducing financial flexibility.

Alpa Laboratories Limited Business Overview & Revenue Model

Company Description

Alpa Laboratories Limited engages in manufacturing, marketing, and selling pharmaceutical finished dosage forms in India. It offers ethical, generic, and over the counter products in various finished dosage forms, including injections, tablets, ca...

Read more

Alpa Laboratories Limited engages in manufacturing, marketing, and selling pharmaceutical finished dosage forms in India. It offers ethical, generic, and over the counter products in various finished dosage forms, including injections, tablets, ca...

How the Company Makes Money

null...

Alpa Laboratories Limited Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	1.11B	1.12B	1.09B	924.10M	1.11B	964.13M
Gross Profit	270.73M	193.99M	188.90M	307.44M	344.08M	316.58M
EBITDA	254.04M	281.01M	229.96M	174.43M	214.31M	130.29M
Net Income	186.58M	195.03M	167.76M	125.83M	140.92M	72.47M
Balance Sheet
Total Assets	2.38B	2.23B	1.82B	1.67B	1.55B	1.40B
Cash, Cash Equivalents and Short-Term Investments	1.39B	1.13B	928.54M	808.42M	702.74M	424.92M
Total Debt	0.00	343.00K	52.47M	23.04M	58.47M	1.92M
Total Liabilities	543.14M	511.59M	304.62M	326.92M	335.08M	327.27M
Stockholders Equity	1.83B	1.71B	1.52B	1.35B	1.22B	1.08B
Cash Flow
Free Cash Flow	89.97M	-21.42M	-27.36M	77.78M	77.49M	-49.20M
Operating Cash Flow	106.65M	92.37M	36.49M	89.04M	99.40M	-17.00M
Investing Cash Flow	-144.58M	-35.13M	-133.36M	21.27M	-156.10M	58.60M
Financing Cash Flow	22.40M	-52.47M	25.83M	-37.93M	54.42M	1.90M

Alpa Laboratories Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 75.60
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ALPA, the sentiment is Positive. The current price of 75.6 is above the 20-day moving average (MA) of 58.84, above the 50-day MA of 64.07, and below the 200-day MA of 83.73, indicating a neutral trend. The MACD of -2.06 indicates Negative momentum. The RSI at 61.97 is Neutral, neither overbought nor oversold. The STOCH value of 72.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ALPA.

Alpa Laboratories Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALPA	64 Neutral	₹1.47B	21.48	―	―	14.53%	-10.49%
BAFNAPH	58 Neutral	₹2.85B	48.53	―	―	-0.77%	2055.99%
BALPHARMA	58 Neutral	₹1.20B	16.40	―	1.62%	-9.07%	5.36%
VAISHALI	52 Neutral	₹661.38M	21.33	―	―	18.35%	-154.65%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AAREYDRUGS	47 Neutral	₹1.77B	84.53	―	―	-17.47%	-50.07%
KREBSBIO	45 Neutral	₹1.25B	-11.90	―	―	-46.31%	-26.28%